Competition authorities have been traditionally reluctant to pursue excessive pricing cases since many of them had failed on the facts. However, in recent years, there has been a resurgence of the topic in pharma-related cases. In particular, the national competition authorities have led the way in 2016, with decisions identifying abusive conduct in Italy (Aspen) and in the United Kingdom (Pfizer/Flynn). The Commission followed shortly after, by initiating its own investigation into Aspen's practices in 2017. This was the first pure excessive pricing investigation carried out by the Commission; in July 2020, Aspen offered commitments to reduce its prices for the products concerned by 73 per cent on average. After a few adjustments made by Aspen in lonstitute abuses of a dominant
Share on
|
|
The UK Competition Authority along with EU Member States cracks down on excessive pricing in the pharmaceutical sector (Pfizer / Flynn / Actavis)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
